HealthEquity (HQY)
Market Price (12/18/2025): $95.33 | Market Cap: $8.2 BilSector: Health Care | Industry: Managed Health Care
HealthEquity (HQY)
Market Price (12/18/2025): $95.33Market Cap: $8.2 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% | Weak multi-year price returns2Y Excs Rtn is -2.0%, 3Y Excs Rtn is -17% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 43x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% | Key risksHQY key risks include [1] the high sensitivity of its custodial revenue to interest rate declines and [2] regulatory or healthcare policy changes that could undermine the market for its core HSA products. | |
| Low stock price volatilityVol 12M is 40% | ||
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Low stock price volatilityVol 12M is 40% |
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Weak multi-year price returns2Y Excs Rtn is -2.0%, 3Y Excs Rtn is -17% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 43x |
| Key risksHQY key risks include [1] the high sensitivity of its custodial revenue to interest rate declines and [2] regulatory or healthcare policy changes that could undermine the market for its core HSA products. |
Valuation, Metrics & Events
HQY Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
The requested time period for the stock movement (8/31/2025 to December 18, 2025) is in the future. Therefore, it is not possible to provide an explanation for a past stock movement that has not yet occurred. However, recent financial reports and news for HealthEquity (HQY) up to the current date indicate several factors that could influence future stock performance.
Here are some recent key points related to HealthEquity's performance and outlook:
1. Strong Financial Results: HealthEquity reported strong Q2 FY26 financial results, with revenue up 9% year-over-year to $325.8 million and net income surging 67% to $59.9 million. The company also achieved a record gross margin of 71% and Adjusted EBITDA of $151.1 million. For Q3 FY26 (ended October 31, 2025), revenue increased 7% year-over-year to $322.2 million, and net income reached $51.7 million. These positive financial results could contribute to a positive outlook for the stock.
2. Growth in HSAs and Total HSA Assets: HealthEquity continues to show growth in its key operating metrics, reporting 10.0 million HSAs (up 6% year-over-year) and Total HSA Assets of $33.1 billion (up 12% year-over-year) in Q2 FY26. In Q3 FY26, HSAs grew to 10.1 million (up 6% year-over-year) and Total HSA Assets reached $34.4 billion (up 15% year-over-year). This expanding base of health savings accounts and assets under management is a positive indicator for the company's core business.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HQY Return | -6% | -37% | 39% | 8% | 45% | 0% | 30% |
| Peers Return | 2% | 13% | -1% | 15% | 18% | -18% | 28% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| HQY Win Rate | 50% | 42% | 58% | 42% | 67% | 42% | |
| Peers Win Rate | 62% | 53% | 48% | 57% | 65% | 45% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| HQY Max Drawdown | -45% | -43% | 0% | -17% | -0% | -20% | |
| Peers Max Drawdown | -44% | -15% | -16% | -5% | -5% | -32% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: WEX, VOYA, ADP, PAYX, FISV. See HQY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)
How Low Can It Go
| Event | HQY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -56.6% | -25.4% |
| % Gain to Breakeven | 130.3% | 34.1% |
| Time to Breakeven | 1,052 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.8% | -33.9% |
| % Gain to Breakeven | 116.4% | 51.3% |
| Time to Breakeven | 314 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.2% | -19.8% |
| % Gain to Breakeven | 93.2% | 24.7% |
| Time to Breakeven | 1,866 days | 120 days |
Compare to HUM, CNC, MOH, PGNY, UNH
In The Past
HealthEquity's stock fell -56.6% during the 2022 Inflation Shock from a high on 1/26/2021. A -56.6% loss requires a 130.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to HQY. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.3% | 16.3% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.1% | -7.1% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.6% | 3.6% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 1.6% | 1.6% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.1% | 14.1% | -5.1% |
| 12312021 | HQY | HealthEquity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 30.4% | 39.3% | 0.0% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.3% | 16.3% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.1% | -7.1% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.6% | 3.6% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 1.6% | 1.6% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.1% | 14.1% | -5.1% |
| 12312021 | HQY | HealthEquity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 30.4% | 39.3% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for HealthEquity
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 106.00 |
| Mkt Cap | 22.6 |
| Rev LTM | 6,738 |
| Op Inc LTM | 2,208 |
| FCF LTM | 1,176 |
| FCF 3Y Avg | 1,189 |
| CFO LTM | 1,349 |
| CFO 3Y Avg | 1,272 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.4% |
| Rev Chg 3Y Avg | 7.1% |
| Rev Chg Q | 7.2% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 26.2% |
| Op Mgn 3Y Avg | 25.8% |
| QoQ Delta Op Mgn LTM | -0.7% |
| CFO/Rev LTM | 30.2% |
| CFO/Rev 3Y Avg | 27.7% |
| FCF/Rev LTM | 23.2% |
| FCF/Rev 3Y Avg | 20.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 22.6 |
| P/S | 3.9 |
| P/EBIT | 14.3 |
| P/E | 23.3 |
| P/CFO | 19.4 |
| Total Yield | 6.2% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 4.6% |
| D/E | 0.3 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.7% |
| 3M Rtn | -8.9% |
| 6M Rtn | -9.5% |
| 12M Rtn | -10.9% |
| 3Y Rtn | 12.5% |
| 1M Excs Rtn | 7.0% |
| 3M Excs Rtn | -10.5% |
| 6M Excs Rtn | -21.9% |
| 12M Excs Rtn | -22.7% |
| 3Y Excs Rtn | -62.8% |
Comparison Analyses
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/3/2025 | -3.0% | -3.0% | |
| 9/2/2025 | 7.5% | 4.7% | 2.1% |
| 6/3/2025 | 9.0% | 3.3% | -1.9% |
| 2/18/2025 | 0.5% | -5.1% | -25.5% |
| 12/9/2024 | -5.6% | -7.8% | -0.7% |
| 9/3/2024 | 5.1% | -5.0% | 0.6% |
| 6/3/2024 | 2.7% | 7.0% | 2.9% |
| 2/21/2024 | 2.7% | 3.7% | 2.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 12 | 11 |
| # Negative | 7 | 12 | 13 |
| Median Positive | 3.7% | 3.8% | 2.9% |
| Median Negative | -5.6% | -5.8% | -7.5% |
| Max Positive | 11.6% | 10.3% | 14.7% |
| Max Negative | -24.6% | -27.4% | -48.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 10312025 | 12032025 | 10-Q 10/31/2025 |
| 7312025 | 9022025 | 10-Q 7/31/2025 |
| 4302025 | 6032025 | 10-Q 4/30/2025 |
| 1312025 | 3182025 | 10-K 1/31/2025 |
| 10312024 | 12092024 | 10-Q 10/31/2024 |
| 7312024 | 9032024 | 10-Q 7/31/2024 |
| 4302024 | 6032024 | 10-Q 4/30/2024 |
| 1312024 | 3222024 | 10-K 1/31/2024 |
| 10312023 | 12052023 | 10-Q 10/31/2023 |
| 7312023 | 9052023 | 10-Q 7/31/2023 |
| 4302023 | 6072023 | 10-Q 4/30/2023 |
| 1312023 | 3302023 | 10-K 1/31/2023 |
| 10312022 | 12082022 | 10-Q 10/31/2022 |
| 7312022 | 9082022 | 10-Q 7/31/2022 |
| 4302022 | 6082022 | 10-Q 4/30/2022 |
| 1312022 | 3312022 | 10-K 1/31/2022 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |